Annexon Highlights Promising Results from Tanruprubart Phase 3 Trial ANNX Stock News
| ANNX Stock | USD 2.48 0.05 1.98% |
Slightly above 62% of Annexon's investor base is looking to short. The analysis of overall sentiment of trading Annexon stock suggests that many investors are alarmed at this time. Annexon's investing sentiment can be driven by a variety of factors including economic data, Annexon's earnings reports, geopolitical events, and overall market trends.
Annexon showcased promising findings from its Phase 3 trial of tanruprubart at the 2025 Peripheral Nerve Society annual meeting in Edinburgh, UK. These r
Read at gurufocus.com
 |
Annexon Fundamental Analysis
We analyze Annexon's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Annexon using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Annexon based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Earnings To Growth
Price To Earnings To Growth Comparative Analysis
PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Annexon Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Annexon stock to make a market-neutral strategy. Peer analysis of Annexon could also be used in its relative valuation, which is a method of valuing Annexon by comparing valuation metrics with similar companies.
Peers
Annexon Related Equities
| ALXO | Alx Oncology | 11.86 | ||||
| ORIC | Oric Pharmaceuticals | 2.57 | ||||
| TCRX | Tscan Therapeutics | 2.34 | ||||
| ITOS | Iteos Therapeutics | 0.1 | ||||
| APLS | Apellis Pharmaceuticals | 0.25 | ||||
| GBIO | Generation Bio | 0.44 | ||||
| ALGS | Aligos Therapeutics | 1.12 |
Additional Tools for Annexon Stock Analysis
When running Annexon's price analysis, check to measure Annexon's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Annexon is operating at the current time. Most of Annexon's value examination focuses on studying past and present price action to predict the probability of Annexon's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Annexon's price. Additionally, you may evaluate how the addition of Annexon to your portfolios can decrease your overall portfolio volatility.